Pooled across 34 studies data from 4.5+ million women showed that MHT use increased breast cancer odds by 15% versus non-use, but regimen-specific effects dominated the aggregate estimate.
In the article that accompanies this editorial, Dumas et al 12 modeled the potential improvements in 5-year disease-free survival (DFS) from hormone receptor–positive early-stage breast cancer if ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results